What Sterofundin ISO Treats: Main Uses and Benefits

Sterofundin ISO is commonly used across conditions presenting with acute episodes that require the restoration of fluid and electrolyte balance. This solution is primarily used for the replacement of extracellular fluid losses in the case of isotonic dehydration, where acidosis is present or imminent. This makes it relevant for managing the symptoms related to systemic imbalance and volume deficit, such as hypovolemia.

This solution is applied in addressing acute electrolyte depletion symptoms and pH imbalance symptoms. It delivers essential ions and a buffering system that supports the body in counteracting metabolic acidosis, while playing a role in managing osmotic stability. This approach is relevant for managing fluid, electrolyte, and pH disturbances.

The solution is commonly used across conditions presenting with acute episodes, such as those requiring intensive perioperative fluid management or fluid resuscitation. It is considered relevant for multiple patient groups, including adults, the elderly, adolescents, and children. The solution is intended to support the management of the overall symptom burden during these difficult episodes.

---

Quick Fact: Relief for Fluid Loss and pH Imbalance

Regulatory References

1. Replacement of extracellular fluid losses in the case of isotonic dehydration, where acidosis is present or imminent

Who Can and Cannot Use Sterofundin ISO?

This section outlines the official eligibility and non-eligibility profiles for Sterofundin ISO, based on authoritative government regulatory documentation.

Contraindicated Populations (Must Not Use)

The medicine is strictly contraindicated and must not be used in individuals with the following conditions:

• Volume and Cardiac Status: Severe congestive cardiac failure, Hypervolaemia (fluid overload), or Severe general oedema.
• Renal Status: Renal failure resulting in oliguria (reduced urine output) or anuria (absence of urine output).
• Electrolyte/Metabolic Balance: Hyperkalaemia (high blood potassium), Hypercalcaemia (high blood calcium), or Metabolic alkalosis (blood is too alkaline).

Eligibility for Age Groups

Sterofundin ISO is generally considered eligible for use across a wide age spectrum, including Adults, the Elderly, Adolescents, Children, Toddlers, and Infants. However, safety and efficacy have not been established for use in newborn infants (below 28 days of age).

Restricted or Conditional Use (Use with Caution)

Special caution and close monitoring are required if the patient has:

• Mild to moderate cardiac insufficiency or impaired renal function.
• Electrolyte disturbances such as hypernatraemia or hyperchloraemia.
• Conditions predisposing to high potassium levels, like adrenocortical insufficiency or extensive tissue damage (e.g., severe burns).
• Toxaemia of pregnancy, hypertension, or aldosteronism.

The official interaction profile of Sterofundin ISO is strictly defined by the electrolyte composition of the solution. The profile is based on additive pharmacodynamic effects that result from co-administration with other substances affecting the body’s electrolyte and fluid balance.

Documented Pharmacodynamic Interactions

• Potassium-Raising Medicines: Co-administration with drugs such as Potassium-Sparing Diuretics (e.g., spironolactone), Tacrolimus, Suxamethonium, and Cyclosporine may lead to an increase in plasma potassium concentration. This carries a documented risk of potentially fatal hyperkalaemia, which is notably increased in individuals with renal failure.

• Sodium-Retaining Medicines: Substances associated with sodium and water retention, including Corticoids/Steroids and Carbenoxolone, may cause an additive effect when combined with this infusion. This can result in increased fluid retention, potentially leading to oedema and hypertension.

• Calcium-Enhanced Effects: The effects of Digitalis Glycosides are enhanced when hypercalcaemia is present. Since the infusion contains calcium, and the supplement Vitamin D may also induce hypercalcaemia, the combination carries a risk of serious cardiac arrhythmia.

Administration-Related Restriction

Regulatory information imposes a mandatory restriction: The solution must not be administered via the same infusion set as a blood transfusion, due to the presence of calcium.

How Sterofundin ISO Works

Sterofundin ISO acts through three interconnected mechanistic domains to influence the body's internal environment, relying on direct replacement and metabolic support rather than receptor-based pharmacology.

---

Volume Restoration and Osmotic Homeostasis

The solution's primary mechanism involves the direct restoration of the extracellular fluid (ECF) volume by supplying an isotonic mixture of water and strong ions. This action dictates the osmotic distribution of fluid across cell membranes by maintaining the osmotic pressure near physiological levels. The resulting physiological effect is the maintenance of systemic tissue perfusion by increasing the fluid volume circulating in the blood vessels.

---

Maintenance of Electrolyte Gradients

This domain involves the coordinated supply of Sodium, Potassium, Calcium, and Magnesium to maintain the correct concentration gradients across cell membranes. This mechanism directly supports the function of ion transporters and channels. The physiological consequence is the support of neuromuscular excitability, which influences stable cardiac and muscle cell function.

---

Metabolic Conversion for Acid-Base Balance

The pH-regulating mechanism relies on the infusion of the metabolic precursors Acetate and Malate, which are converted into Bicarbonate ( HCO3^-) via the body's own oxidative processes, such as the TCA cycle . This conversion consumes H^+ ions, thus increasing the plasma's buffering capacity and leading to an adjustment of extracellular pH towards the physiological norm. This domain is important because the maintenance of stable pH is required for the optimal conformation and function of all body enzymes and proteins.

Sterofundin ISO is designed exclusively for intravenous use and is administered as a controlled infusion via a drip. The administration of this crystalloid solution can be introduced through peripheral veins at a rate and volume determined by the patient's specific fluid status and clinical requirements.

Dosing Regimens

The total volume administered is calculated over a 24-hour period. For adults, the elderly, and adolescents, the recommended daily dose generally ranges from 500 millilitres up to 3 litres. This volume corresponds to 1 to 6 mmol of sodium per kilogram of body weight per 24 hours.

For the pediatric population (babies and children from 28 days to 11 years), the dosing is weight-based, ranging from 20 millilitres to 100 millilitres per kg of body weight per 24 hours. The safety and efficacy of the solution in newborn infants (below 28 days) have not been established.

Procedural and Time Constraints

Administration is not fixed to a specific cycle but continues only for as long as there is a documented indication for fluid replacement. Standard procedure involves the mandatory monitoring of the patient's fluid balance, plasma electrolyte concentrations, and blood pH throughout the entire period of infusion. Furthermore, if the solution is delivered by rapid infusion under pressure, all air must be completely withdrawn from the container and the infusion set to ensure appropriate administration.

Research evidence / Overview of studies for Sterofundin ISO

Evidence for Use in Fluid and Electrolyte Balance

Research has examined the use of this solution and similar plasma-adapted fluids primarily in adult surgical patients and those requiring volume replacement, using short-term Randomized Controlled Trials (RCTs) and Systematic Reviews. Studies explore how temporary physiological imbalance is measured when using this solution compared to Normal Saline. Findings describe patterns observed where the use of balanced crystalloids was observed in some studies to correlate with the maintenance of physiologic acid-base parameters. Trials reported data showing patterns related to a lower incidence of hyperchloremic metabolic acidosis in the balanced fluid group. However, follow-up durations were limited, and comparative evidence is lacking to definitively show whether the research supports choosing this specific solution over other available balanced crystalloids. The results apply only to the populations studied.

---

Studies in Critical Care and Fluid Resuscitation

Research examined the use of balanced crystalloids as part of fluid resuscitation protocols for critically ill adult patients with conditions such as Sepsis or Septic Shock. Studies evaluated both physiological and clinical endpoints, including the incidence of Acute Kidney Injury (AKI) and composite mortality. Research explored whether the use of balanced crystalloids was associated with a difference in the reported incidence of AKI compared to Normal Saline. Findings were mixed regarding ultimate clinical outcomes, such as mortality, across the aggregated evidence.

---

Research in Perioperative Settings and Specific Patient Cohorts

Research explored the use for perioperative fluid management during major surgery. Studies monitored outcomes related to systemic imbalance, noting that the solution was observed in some studies to correlate with the maintenance of physiological parameters compared to Normal Saline. This solution was studied for fluid replacement in adults with Diabetic Ketoacidosis (DKA).

Evidence in Pediatric Patients

The use of this solution in children and infants has been evaluated in smaller-scale RCTs, often during major surgical procedures. However, sample sizes were modest, and comparative evidence is lacking against other balanced solutions, meaning the subgroup findings are uncertain.

---

Long-Term Evidence and Follow-Up

The available research primarily explores short-term symptom changes and immediate physiological effects. There is limited information for long-term outcomes regarding the durability of physiological stabilization or effects on a patient's overall health years after receiving the infusion.

---

Research Gaps and Areas of Uncertainty

The evidence landscape highlights what is known—and what is still uncertain. Comparative evidence is lacking for a wide range of head-to-head comparisons against other major balanced solutions. Overall, the data are still emerging, particularly regarding how the initial findings translate into consistently different outcomes reflecting daily functioning or activity level in patients over extended periods.

Key Studies & References A meta-analysis of balanced versus normal saline crystalloid solutions for fluid resuscitation in patients with DKA

Common questions about Sterofundin ISO (FAQ)

Q: Is Sterofundin ISO just salt water, or is it different?

Official product information describes Sterofundin ISO as a plasma-adapted electrolyte solution. It contains several essential salts, including sodium, potassium, calcium, and magnesium. Additionally, it includes buffer precursors called acetate and malate, whose addition distinguishes it from simple saline solutions.

Q: Why is it called 'ISO'?

The 'ISO' in the name is a reference to the solution's isotonic properties. This means that the fluid's concentration is similar to the normal concentration found in blood plasma and other body fluids. Maintaining this physiological balance is a key purpose of the solution.

Q: Is Sterofundin ISO commonly used in hospitals?

According to official regulatory documents, Sterofundin ISO is a solution designed exclusively for administration via the intravenous route. It is specifically intended for use in hospital settings for fluid and electrolyte replacement, which is its typical use environment.

Q: Does Sterofundin ISO contain sugar or glucose?

The officially documented composition of Sterofundin ISO does not list any sugar, glucose, or dextrose as an active or inactive ingredient. The solution is formulated only with essential electrolytes and the buffer system (acetate and malate).

Q: Is Sterofundin ISO suitable for people with diabetes?

Since the product does not contain any sugar, official information states the product is used under medical supervision, and its composition does not include sugar. Furthermore, research summarized in regulatory documents has examined the use of the solution for fluid replacement in adult patients with Diabetic Ketoacidosis (DKA).

Q: Does Sterofundin ISO interact with blood pressure medication?

Official drug interaction data notes that co-administration with drugs that cause sodium and water retention, such as certain steroid hormones, may lead to an additive effect. The combination is associated with a documented risk of increased fluid retention or swelling.

Q: Can Sterofundin ISO be given alongside other common medicines?

The official product information specifies that compatibility for co-administration should be verified by the healthcare team before administration. Regulatory documents list several specific drug classes that interact with the solution and impose a mandatory restriction that the solution is not to be administered with a blood transfusion.

Q: Why would a doctor choose Sterofundin ISO instead of other IV fluids?

Official documents describe this solution as being plasma-adapted because its electrolyte concentration closely resembles the body's natural fluids. A key feature is its unique buffer system (acetate and malate), which is designed to help support the body's natural acid-base balance.

Q: What happens if Sterofundin ISO is administered too fast?

Regulatory documents state that too rapid administration or overuse may lead to water and sodium overload, which carries a risk of swelling (oedema). Excessive administration can also cause high levels of certain electrolytes, which may lead to issues such as cardiac rhythm changes.

Q: Is Sterofundin ISO a prescription-only medicine?

The solution’s status as an intravenous drug for use in hospital settings indicates it is subject to official regulatory control and administration under medical guidance.

Q: Where is Sterofundin ISO approved for use?

Official authorization for this solution is granted by various government bodies, including the European Medicines Agency (EMA) and multiple national authorities. These agencies hold the official documentation required for the solution to be marketed and used in their respective territories.

Q: Is Sterofundin ISO ever used in emergency situations?

Research summarized in regulatory documents has examined the use of this solution as part of fluid resuscitation protocols. This research was focused on critically ill adult patients with severe conditions, such as Sepsis or Septic Shock.

Q: Is it normal to feel cold while receiving Sterofundin ISO?

The official list of adverse reactions associated with the method of intravenous administration includes a febrile response (fever). Other reported reactions related to the administration technique include local pain or irritation at the injection site.

Q: Can Sterofundin ISO be mixed with other medicines in the same drip?

The official product information states that the solution is not to be administered in the same infusion set as a blood transfusion due to the presence of calcium. Compatibility for mixing with other medicines must be specifically verified by a healthcare professional prior to use.

Q: What is the shelf-life of the product before it is opened?

The medicine's expiration date, or shelf-life, is strictly defined in the official regulatory documentation. This information is a mandatory part of the Pharmaceutical Particulars section and can be found on the product packaging.

Q: What is the primary ingredient that makes Sterofundin ISO effective?

The effectiveness of the solution relies on the coordinated action of all its components. This includes essential electrolytes that maintain fluid dynamics and the buffer precursors (Acetate and Malate), which are converted in the body to help support acid-base balance.

Q: What does the patient information leaflet say about Sterofundin ISO?

The Patient Information Leaflet (PIL), or Package Leaflet, is a regulatory document required to accompany the medicine. It contains the official safety and use information from the regulatory filing, presented in a clear, patient-friendly format.

How to Store and Dispose of Sterofundin ISO?

Sterofundin ISO solution for infusion must be stored in strict compliance with the conditions defined in the official regulatory labeling.

Storage and Protection Rules

The medicine must be stored where the container is protected from extreme temperatures. It is a mandatory requirement that the product must not be refrigerated or frozen. For the solution packaged in plastic containers, storage must not exceed 25°C.

Prior to use, the solution must be visually clear and free of particles, and the container must not be damaged or leaking. This medicine must be kept out of the sight and reach of children.

Disposal Requirements

Sterofundin ISO is strictly for single use only. Any solution remaining in the container after the administration is complete must be immediately discarded. All unused product or waste material must be disposed of in accordance with local regulatory requirements.